Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Prepaid Assets: 2013-2025

Historic Prepaid Assets for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to $6.8 million.

  • Theravance Biopharma's Prepaid Assets fell 12.08% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 12.08%. This contributed to the annual value of $4.3 million for FY2024, which is 63.14% down from last year.
  • As of Q3 2025, Theravance Biopharma's Prepaid Assets stood at $6.8 million, which was up 21.16% from $5.6 million recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Prepaid Assets peaked at $12.4 million during Q2 2021, and registered a low of $4.1 million during Q1 2025.
  • For the 3-year period, Theravance Biopharma's Prepaid Assets averaged around $7.0 million, with its median value being $6.8 million (2025).
  • As far as peak fluctuations go, Theravance Biopharma's Prepaid Assets soared by 82.79% in 2021, and later slumped by 63.14% in 2024.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Prepaid Assets stood at $8.6 million in 2021, then fell by 10.27% to $7.7 million in 2022, then spiked by 51.04% to $11.6 million in 2023, then plummeted by 63.14% to $4.3 million in 2024, then fell by 12.08% to $6.8 million in 2025.
  • Its Prepaid Assets was $6.8 million in Q3 2025, compared to $5.6 million in Q2 2025 and $4.1 million in Q1 2025.